Cidara Therapeutics, Inc. (CDTX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 San Diego, CA, 미국. 현재 CEO는 Jeffrey L. Stein.
CDTX 을(를) 보유 IPO 날짜 2015-04-15, 38 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $5.61B.
Cidara Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing long-acting anti-infective treatments for infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel echinocandin antifungal designed to treat and prevent invasive fungal infections such as candidemia and invasive candidiasis, which carry high mortality rates. Cidara also leverages its Cloudbreak platform to develop conjugate therapies for preventing and treating viral infections, including influenza, RSV, HIV, and COVID-19. Founded in 2012 and based in San Diego, California, the company was formerly known as K2 Therapeutics before rebranding to Cidara Therapeutics in 2014.
